Leading the Way for Pediatric Behavioral Health​

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

child pressing on Cognoa C
child pressing on Cognoa C

We are developing digital diagnostic and therapeutic products with the goal of enabling earlier and more equitable care for behavioral health conditions.

Now Available: Canvas Dx™(Rx only)

Developing Digital Diagnostic and Therapeutic Products for Behavioral Health

Provider for pediatrics behavioral health

Providers

We are designing digital products that may enable providers to diagnose behavioral health conditions earlier, starting with autism.

 

happy family mom dad son and daughter

Parents

We seek to support parents and caregivers
to act on early concerns about their child’s development.

 

female professional

Careers

Join our diverse team with opportunities spanning product, engineering, data science,
and clinical.

 

Recent Press Releases

Cognoa named one of Fierce Medtech’s “Fierce 15” Companies of 2021

Cognoa is designated as one of the most most promising private med tech companies in the industry.

Publications in Peer Reviewed Journals

FDA Breakthrough Designation Products

Cognoa has received Breakthrough Device Designation from the FDA for both its lead products, a digital diagnosis aid and therapeutic for autism. 

Early Intervention Lasts a Lifetime

Autism diagnosis and intervention during the critical early neurodevelopmental period improves lifelong outcomes for children with autism.1-3 Early intervention within the neurodevelopmental window can yield significant improvements in behavioral, social, emotional, and cognitive functioning among individuals living with autism.¹
toddlers playing at water table together
  1. Estes A, et al. J Am Acad Child Adolesc Psychiatry. 2015;54(7):580-587.
  2. Strain PS, Bovey EH. Topics in Early Childhood Special Education. 2011;31(3):133-154.
  3. Peters-Sheffer N, et al. Res Autism Spectr Disord. 2011;5(1):60-69.

We are committed to developing products for earlier diagnosis and treatment.

Copyright © 2022 Cognoa, Inc. All rights reserved.